The Open-angle Glaucoma Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

 

Key takeaways from the Open-angle Glaucoma Market Report

• As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries.
• According to DelveInsight’s analysis, in 2019, there were 2,749,378 cases of Open-Angle Glaucoma in the US.
• DelveInsight’s analysis shows that in 2019 there were 7,941,564 and 882,396 cases of POAG and Secondary OAG, respectively, in the 7MM.
• Open-Angle Glaucoma companies such as Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp, Novartis/Alcon Research, Allergan, and several others.
• Open Angle Glaucoma therapies such as ROCKLATAN, Rhopressa, XELPROS (latanoprost ophthalmic emulsion) 0.005%, EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl), VYZULTA, TAPCOM/ DE-111 (Tafluprost/timolol maleate), GLANATEC, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, ZIOPTAN (tafluprost), DuoTrav PQ (travoprost/timolol), TRAVATAN Z (travoprost ophthalmic solution) 0.004%, LUMIGAN 0.01% (bimatoprost ophthalmic solution), Bimatoprost SR (Sustained-Release), and several others.

 

Know which therapies are expected to grab major Open-angle Glaucoma Market Share @ Open-angle Glaucoma Market Size

 

Open-angle Glaucoma Overview

Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects, due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. Primary open-angle glaucoma (POAG) and Secondary open-angle glaucoma. POAG is a subset of glaucoma defined by an open, normal-appearing anterior chamber angle and raised intraocular pressure (IOP), with no other underlying disease. In Secondary open-angle glaucoma, there is an identifiable cause of increased eye pressure, resulting in optic nerve damage and vision loss.

The sign and symptoms of OAG includes an increase in IOP, open anterior chamber angle and optic disc changes seen on clinical examination such as high cup to disc ratio, cup to disc ratio asymmetry between eyes, vertical elongation of the cup, etc.

 

The Open-angle Glaucoma Risk Factors include older age, family history of glaucoma, African ancestry, nearsightedness, high IOP, low blood pressure, use of topical corticosteroids, inflammation, and tumor. There are several risk factors like age >60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems, which are associated with this indication and, thus, the treatment pattern varies accordingly.

 

Open-Angle Glaucoma Epidemiology Segmentation in the 7MM

• Total Open-Angle Glaucoma Prevalent Population
• Open-Angle Glaucoma Gender-specific Diagnosed Prevalence
• Open-Angle Glaucoma Age-specific Diagnosed Prevalence
• Total Open-Angle Glaucoma Diagnosed Prevalent Population
• Open-Angle Glaucoma Type-specific Diagnosed Prevalent Population

 

For further information of this report to understand which factors are driving Open-Angle Glaucoma epidemiology trends @ Open-Angle Glaucoma Epidemiological Insights

 

Open-Angle Glaucoma Treatment Market

The main goal of glaucoma treatment is to increase the quality of life through the reduction of IOP to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable, and affordable. However, the medical treatment of glaucoma has associated side effects, complications, and costs.

 

Open-Angle Glaucoma Market Insights

There are three mainstays for lowering eye pressure, i.e. medication, laser, and surgery. The two types of laser treatments currently used are Selective Laser Trabeculoplasty (SLT) and Argon Laser Trabeculoplasty (ALT). Surgery for OAG includes Cataract Surgery, Micro-Invasive Glaucoma Surgery (MIGS), Trabeculectomy, Drainage Implant Surgery, and Ciliary Body Ablation. There is an array of medications to lower the intraocular pressure in OAG, which are divided into five major classes, i.e., Prostaglandin Analogs, Beta Blockers, Diuretics, Cholinergic Agonists (Parasympthomimetics), and Alpha Agonists.

 

Open-Angle Glaucoma Emerging Therapy Assessment

Open-Angle Glaucoma Treatment aims to lower the IOP and thus reduce the risk of progressive loss of vision, using medications, laser therapy, or conventional surgery. Open-Angle Glaucoma Treatment options are rapidly expanding. However, there is no cure available still.

 

Learn more about the Open-Angle Glaucoma Therapies in clinical trials @ Drugs for Open-Angle Glaucoma Treatment

 

Open-Angle Glaucoma Market Drivers

• Rich emerging pipeline
• Development of advanced anti-glaucoma medications
• Patient-friendly dosage regimes
• Rise in awareness
• Development of treatment methods to tackle the situation of non-adherence

 

Open-Angle Glaucoma Market Barriers

• Lack of animal models
• Socioeconomic barriers
• Lack of patient pool due to under-diagnosis

 

Table of Content

1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Competitive Intelligence Analysis for Open-Angle Glaucoma

4. Open-Angle Glaucoma: Market Overview at a Glance

5. Open-Angle Glaucoma: Disease Background and Overview

6. Patient Journey

7. Open-Angle Glaucoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Open-Angle Glaucoma Unmet Needs

10. Key Endpoints of Open-Angle Glaucoma Treatment

11. Open-Angle Glaucoma Marketed Products

12. Open-Angle Glaucoma Emerging Therapies

13. Open-Angle Glaucoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Open-Angle Glaucoma Market Outlook

16. Access and Reimbursement Overview of Open-Angle Glaucoma

17. KOL Views

18. Open-Angle Glaucoma Market Drivers

19. Open-Angle Glaucoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Get in touch with our Business Executive @ Open-Angle Glaucoma Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight